BCG Vaccines Market – By Age Group (Pediatrics, Adults), By Application (Tuberculosis, Bladder Cancer), By End-use (Hospitals, Clinics) & Forecast, 2024 – 2032

BCG Vaccines Market – By Age Group (Pediatrics, Adults), By Application (Tuberculosis, Bladder Cancer), By End-use (Hospitals, Clinics) & Forecast, 2024 – 2032

BCG Vaccines Market Size

BCG Vaccines Market size was valued at USD 88.3 million in 2023 and is anticipated to witness growth at a CAGR of 5.4% between 2024 and 2032. BCG vaccines are live attenuated vaccines derived from a strain of Mycobacterium bovis, a bacterium closely related to Mycobacterium tuberculosis, the causative agent of tuberculosis (TB).

To get key market trends

  Download Free Sample

BCG vaccines stimulate the immune system to develop immunity against TB, reducing the risk of severe forms of the disease, such as meningitis and disseminated TB, in vaccinated individuals. BCG is also utilized as a form of immunotherapy in the treatment of non-muscle invasive bladder cancer. The BCG vaccines market is experiencing growth driven by the growing incidence of tuberculosis (TB) coupled with the rising awareness and adoption of vaccination programs.
 

What are the growth opportunities in this market?

 Download Free Sample

TB remains a major global health issue, with millions of new cases reported every year. For instance, according to the World Health Organization, in 2022, there were 2.2 million new TB cases globally. Despite advancements in healthcare, TB continues to disproportionately affect low- and middle-income countries, where healthcare infrastructure may be insufficient to manage the disease effectively. The burden is further compounded by factors such as poverty, malnutrition, and HIV/AIDS, which weaken immune systems and increase susceptibility to TB infection.

Additionally, communities worldwide are becoming more health-conscious and informed about preventive healthcare measures. This heightened health literacy extends to understanding the importance of vaccination in preventing infectious diseases like TB. As people become more aware of the risks posed by TB and the effectiveness of BCG vaccination in mitigating those risks, the demand for BCG vaccines rises correspondingly.

BCG Vaccines Market Trends

• The rise in R&D activity aimed to enhance the efficacy, safety, and delivery mechanisms of BCG vaccines, addressing longstanding challenges in tuberculosis prevention and control plays a pivotal role in fueling the market growth for BCG vaccines.
• In response to emerging global health threats and the persistent burden of TB, stakeholders prioritized innovative approaches to vaccine development. Advanced research methodologies, including genomics, proteomics, and computational modeling, have enabled scientists to gain deeper insights into TB pathogenesis and immune response mechanisms. These insights guided the design of next-generation BCG vaccines with improved immunogenicity and broader protection against diverse TB strains, including drug-resistant variants.
• Additionally, collaborative R&D initiatives have fostered partnerships between academia, industry, and public health agencies, driving innovation and accelerating the translation of research findings into tangible vaccine products. Strategic alliances and technology transfer agreements have facilitated the transfer of vaccine technologies and expertise, expediting vaccine development timelines and bolstering market competitiveness.
• Furthermore, the surge in R&D investments also supports the exploration of novel vaccine delivery platforms and adjuvants, optimizing vaccine formulations for enhanced stability, potency, and ease of administration. Breakthroughs in vaccine delivery technologies, such as microneedle patches and oral vaccines, offer promising alternatives to traditional injection-based approaches, improving vaccine accessibility and acceptance.

BCG Vaccines Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

Based on age group, the market is segmented into pediatrics and adults. The pediatrics segment held a dominant market share of 84.9% in 2023.

• BCG vaccination is typically administered during infancy as part of the routine immunization schedule in many countries, especially those with high TB burden. Governments and healthcare authorities recommend universal BCG vaccination for newborns to provide early protection against severe forms of TB, such as TB meningitis and disseminated TB, which are more prevalent in young children.
• Additionally, BCG vaccination offers long-term protection against TB, with studies demonstrating its efficacy in reducing TB incidence and severity into adulthood. By vaccinating children early in life, healthcare providers can establish a foundation of immunity that persists throughout their lifespan, contributing to sustained TB control efforts and public health outcomes.
• Furthermore, infants and young children are particularly vulnerable to TB infection and its complications due to their immature immune systems. BCG vaccination aims to bolster their immune responses and reduce the risk of TB-related morbidity and mortality during early childhood when the disease burden is highest, driving the widespread adoption of BCG vaccines.

Based on application, the BCG vaccines market is classified into tuberculosis and bladder cancer. The tuberculosis segment accounted for the highest market share and was valued at USD 72.3 million in 2023.

• TB continues to pose a significant global health burden. For instance, according to the TBC Indonesia, in 2021, there were 969,000 TB cases in Indonesia. High TB prevalence in developing regions underscores the urgent need for effective TB prevention strategies, including vaccination.
• Additionally, many countries with high TB burden integrate BCG vaccination into their national immunization programs, targeting infants shortly after birth to provide early protection against TB. These programs ensure widespread vaccine coverage and contribute to the dominance of the tuberculosis segment in the market.

Learn more about the key segments shaping this market

 Download Free Sample

Based on end-use, the BCG vaccines market is categorized into hospitals and clinics. The hospitals segment is projected to reach USD 101.9 million by 2032.

• Hospitals serve as primary healthcare providers in many regions, offering a wide range of preventive and curative services, including vaccination programs. Given the importance of BCG vaccination in preventing TB, hospitals play a central role in implementing national immunization schedules and ensuring vaccine access for both inpatients and outpatients.
• Additionally, hospitals typically have established vaccine distribution networks, allowing them to procure BCG vaccines directly from manufacturers or through government agencies and vaccine suppliers. This streamlined supply chain facilitates timely access to BCG vaccines and enables hospitals to maintain sufficient vaccine stock levels to meet patient demand.
• Furthermore, hospitals often specialize in pediatric and maternal healthcare, catering to the vaccination needs of newborns, infants, and pregnant women. BCG vaccination is routinely administered to newborns shortly after birth as part of the standard immunization schedule in many countries, making hospitals the primary venue for vaccine delivery in these vulnerable population groups. Such aforementioned factors drive the growth of this segment.

Looking for region specific data?

 Download Free Sample

Asia Pacific BCG vaccines market is predicted to grow at a CAGR of 5.6% over the analysis timeframe.

• The Asia Pacific region is home to a significant proportion of the global TB burden. According to the World Health Organization, in 2022, eight countries, including India, China, Indonesia, and the Philippines, accounted for more than two-thirds of global TB cases.
• The prevalence of TB in the region underscores the critical need for effective TB prevention strategies, including BCG vaccination, driving demand for BCG vaccines.
• Additionally, Asia Pacific is the most populous region in the world, accounting for over half of the global population. The sheer size of the population creates a substantial market for BCG vaccines, as healthcare systems strive to vaccinate millions of infants and children annually as part of national immunization programs, contributing to the market growth in the region.

India BCG vaccines market is anticipated to grow at a CAGR of 5.7% to reach USD 26.9 million by the end of the forecast timeframe.

• BCG vaccination is an integral component of India's national immunization program, which aims to vaccinate newborns and infants to protect them against severe forms of TB. Government-led initiatives prioritize TB control efforts and ensure equitable access to BCG vaccines across diverse socio-economic segments.
• Additionally, India's large population provides a substantial market for BCG vaccines, with millions of infants born each year requiring vaccination. The scale of vaccination efforts in India contributes significantly to the country's market share in the market.

China BCG vaccines market is projected to grow remarkably in the coming years.

• China has made substantial investments in healthcare infrastructure, including vaccination clinics, cold chain logistics, and primary healthcare facilities. The expansion of healthcare infrastructure supports the delivery and distribution of BCG vaccines nationwide.
• Additionally, China boasts a robust vaccine industry with indigenous manufacturing capabilities and a focus on vaccine research and development. Domestic vaccine manufacturers play a significant role in meeting the country's demand for BCG vaccines, driving market growth.

South Africa is experiencing high market growth in the BCG vaccines market.

• South Africa's high TB incidence rates, compounded by the HIV/AIDS epidemic, drive demand for BCG vaccines as a preventive measure. Vaccination efforts are particularly crucial in regions with high disease prevalence and among populations at increased risk of TB infection.
• Additionally, Community engagement and awareness campaigns promote BCG vaccination as a vital public health intervention for TB prevention. Efforts to educate communities about the benefits of vaccination and encourage vaccine uptake, driving demand for BCG vaccines in the country.

BCG Vaccines Market Share

The BCG vaccines industry is characterized by the presence of several established and emerging players that offer a variety of products across the globe. Key players dominate the market due to their extensive product portfolios, strong distribution networks, and significant R&D investments. These companies leverage their global reach and advanced manufacturing capabilities to maintain competitive advantages.

Market players compete based on factors such as product quality, innovation, regulatory compliance, customer service, and pricing strategies. The market is also witnessing increased competition from emerging biotech firms focusing on innovative BCG formulations and delivery methods.

BCG Vaccines Market Companies

Prominent players operating in the BCG vaccines industry include

• AJ Biologics Sdn Bhd
• BCG Vaccine Laboratory
• Biomed Lublin S.A.
• GSBPL
• Japan BCG Laboratory
• Merck & Co., Inc.
• Microgen
• Serum Institute of India Pvt. Ltd.
• Taj Pharmaceuticals Limited
• Zydus Group

BCG Vaccines Industry News

• In May 2024, ImmunityBio, Inc. signed an exclusive global arrangement with the Serum Institute of India to supply ImmunityBio with Bacillus Calmette-Guerin (BCG). The agreement covers the manufacturing of standard BCG (sBCG) that is currently approved for use outside the U.S., as well as a next-generation recombinant BCG (iBCG) undergoing testing, intended for use in combination with ImmunityBio’s ANKTIVA (nogapendekin alfa inbakicept-pmln) for currently approved and potential future indications. This collaboration may help the company to acquire an enhanced customer base and capitalize on emerging opportunities.

The BCG vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments

Click here to Buy Section of this Report

Market, By Age Group

• Pediatrics
• Adults

Market, By Application

• Tuberculosis
• Bladder cancer

Market, By End-use

• Hospitals
• Clinics

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • India
  • China
  • Indonesia
  • Philippines
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa